Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR | |
Wu, Jianwei2; Chen, Wenteng2; Xia, Guangxin3; Zhang, Jing3; Shao, Jiaan2; Tan, Biqin1; Zhang, Chunchun3; Yu, Wanwan2; Weng, Qinjie1; Liu, Haiyan3 | |
刊名 | ACS MEDICINAL CHEMISTRY LETTERS
![]() |
2013-10 | |
卷号 | 4期号:10页码:974-978 |
关键词 | Anticancer kinase inhibitor EGFR conformationally constrained |
ISSN号 | 1948-5875 |
DOI | 10.1021/ml4002437 |
文献子类 | Article |
英文摘要 | This letter describes the construction of conformationally constrained quinazoline analogues. Structure-activity relationship studies led to the identification of the lead compound 9n. Compound 9n exhibits effective in vitro activity against A431(WT,overexpression) and H1975([L858R/T790M]) cancer cell lines but is significantly less effective against EGFR negative cancer cell lines (SW620, A.549, and 1(562). Compound 9n was also assessed for potency in enzymatic assays and in vivo antitumor studies. The results indicated that 9n is a potent kinase inhibitor against both wild-type and T790M mutant EGFR kinase. Meanwhile, an oral administration of 9n at a dose of 200 mg/kg produced a considerable antitumor effect in a A431 xenograft model, as compared to gefitinib. A preliminary pharmacokinetic study of 9n also indicates it has good pharmacokinetic properties, and therefore, it is a good starting point for further development. |
资助项目 | National Natural Science Foundation of China[81072516] ; National Natural Science Foundation of China[81273356] ; Natural Science Foundation of Zhejiang Province[Z2110655] ; Program for Zhejiang Leading Team of ST Innovation[00000000] ; Osteoporosis and Breast Cancer Research Center, USA[00000000] |
WOS关键词 | GROWTH-FACTOR RECEPTOR ; TYROSINE KINASE INHIBITORS ; NEUTRAL 5-SUBSTITUTED 4-ANILINOQUINAZOLINES ; ORALLY-ACTIVE INHIBITORS ; LUNG-CANCER MODELS ; IRREVERSIBLE INHIBITORS ; THERAPY ; POTENT ; HER-2 |
WOS研究方向 | Pharmacology & Pharmacy |
语种 | 英语 |
出版者 | AMER CHEMICAL SOC |
WOS记录号 | WOS:000326367200019 |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/277433] ![]() |
专题 | 药物化学研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
通讯作者 | Shen, Jingkang |
作者单位 | 1.Zhejiang Univ, Sch Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China; 2.Zhejiang Univ, Zhejiang Prov Key Lab Anticanc Drug Res, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China; 3.Shanghai Pharmaceut Holding Co Ltd, Cent Res Inst, Shanghai, Peoples R China; 4.Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
推荐引用方式 GB/T 7714 | Wu, Jianwei,Chen, Wenteng,Xia, Guangxin,et al. Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR[J]. ACS MEDICINAL CHEMISTRY LETTERS,2013,4(10):974-978. |
APA | Wu, Jianwei.,Chen, Wenteng.,Xia, Guangxin.,Zhang, Jing.,Shao, Jiaan.,...&Yu, Yongping.(2013).Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.ACS MEDICINAL CHEMISTRY LETTERS,4(10),974-978. |
MLA | Wu, Jianwei,et al."Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR".ACS MEDICINAL CHEMISTRY LETTERS 4.10(2013):974-978. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论